Genomics IPOs Sizzle In Summer; Elitra In Line To Test Investor Appetite
Elitra Pharmaceuticals is in line to test the size of Wall Street's healthy appetite for genomic-related initial public offerings.
You may also be interested in...
Genaissance Pharmaceuticals is developing a pharmacogenomics-based assay for predicting an individual occurrence of agranulocytosis associated with the antipsychotic clozapine (Novartis' Clozaril and generics)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011